Skip to content
AnalystLens
Back to HALOBalance Sheet

Halozyme Therapeutics Long-Term Debt 2011-2026 | HALO

Annual FY2011–FY2025 · quarterly through Q3 FY2026

Latest annual · FY2025

$2.14B

+42.3%YoY vs FY2024Source: 10-KFY2025

From $0 in FY2011 to $2.14B in FY2025.

By quarter▲▼ vs a year before
Fiscal yearQ1Q2Q3Q4
FY26$1.9B+28.4%$1.9B+28.4%$2.9B+94.9%Not reported
FY25$1.5B+0.4%$1.5B+0.4%$1.5B+0.4%$2.1B+42.3%
FY24$1.5B+0.4%$1.5B+0.4%$1.5B+0.4%$1.5B+0.4%
FY23$1.5B+89.6%$1.5B+30.4%$1.5B−0.5%$1.5B−0.5%
FY22$788M+0.4%$1.1B+46.0%$1.5B+91.3%$1.5B+91.3%

Shaded by size: darkest is the largest quarter shown; ringed is the latest reported; a dash marks a quarter with no separate figure. Each quarter sits by its period-end date.

Key Statistics

Trend DirectionStable
CAGR

N/A

FY2020
$0
FY2025
$2.14B

5 years selected · on the chart

Long-Term Debt History

Year-over-year comparison from 10-K annual reports

  1. $2.14B
YoY changeLargest recent move+91.3%in FY22Latest +42.3%

2 older moves run past ±150% (largest +998.4%); point at, tap or drag across the bars to read one.

Long-Term Debt, period by period

PeriodValueChangeSource
FY2025$2.14B+42.3%10-K
FY2024$1.51B+0.4%10-K
FY2023$1.50B−0.5%10-K
FY2022$1.51B+91.3%10-K
FY2021$787.3M—10-K
FY2020$0−100.0%10-K
FY2019$383.0M+998.4%10-K
FY2018$34.9M−72.1%10-K
FY2017$125.1M−37.2%10-K
FY2016$199.2M+612.3%10-K
FY2015$28.0M−43.9%10-K
FY2014$49.9M+0.2%10-K
FY2013$49.8M+67.8%10-K
FY2012$29.7M—10-K
FY2011$0—10-K

What is long-term debt?

Long-term debt includes bonds, mortgages, and other borrowings with maturities greater than one year.

What is Halozyme Therapeutics's current long-term debt?

Halozyme Therapeutics (HALO) annual long-term debt for 2025 was $2.14B, a 42.29% increase from 2024. Halozyme Therapeutics long-term debt for the quarter ending September 30, 2026 was $2.94B.

What was Halozyme Therapeutics's long-term debt in 2024?

Halozyme Therapeutics annual long-term debt for 2024 was $1.51B, a 0.44% increase from 2023.

What was Halozyme Therapeutics's long-term debt in 2023?

Halozyme Therapeutics annual long-term debt for 2023 was $1.50B, a 0.45% decline from 2022.

Company
Halozyme Therapeutics
Ticker
HALO
Sector
Healthcare
Industry
Biological Products, (No Diagnostic Substances)